Neurological
Refine Search
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Sage Therapeutics will down tools on its dalzanemdor program, after the Phase II DIMENSION trial missed both primary and secondary endpoints. 21 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November meeting, notable among which was a reversal of a previous rejection of Alzheimer’s drug Leqembi (lecanemab). 15 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Biotechnology
Swiss clinical-stage biopharma AC Immune saw its shares gain 8% to $3.38 in US trading this morning, after it released positive interim safety and immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056. 14 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the treatment of AADC (aromatic L-amino acid decarboxylase) deficiency, making it the first-ever gene therapy approved in the USA that is directly administered to the brain. 14 November 2024
Pharmaceutical
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm MEDICE Arzneimittel Pütter. 14 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Pharmaceutical
US drugmaker AbbVie was trading more than 11% lower early on Monday afternoon in New York. 11 November 2024
Pharmaceutical
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research.. 11 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
The US Food and Drug Administration yesterday approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients aged two and older. 26 June 2020
Biotechnology
VistaGen Therapeutics, a US biotech with a pipeline focused on antidepressants, and EverInsight Therapeutics have entered into a strategic licensing and collaboration agreement for the clinical development and commercialization of PH94B, VistaGen's novel, rapid-onset neurosteroid drug candidate for multiple anxiety-related disorders, in Greater China, South Korea and Southeast Asia. 26 June 2020
Pharmaceutical
Japanese pharma major Eisai has received marketing approval of Equfina (safinamide mesylate) for treatment of idiopathic Parkinson’s disease as adjunctive therapy with levodopa-containing products in patients with end of dose motor fluctuations from South Korea’s Ministry of Food and Drug Safety). 25 June 2020
Biotechnology
US neuroscience-focused start-up Yumanity Therapeutics has entered into a strategic research collaboration and license agreement with pharma giant Merck & Co focused on accelerating the development of new treatments for neurodegenerative diseases. 24 June 2020
Pharmaceutical
Biohaven Pharmaceutical’s shares were down 4.3% at $69.91 in morning trading today, after it reported mixed top-line results from its proof-of-concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD). 24 June 2020
Pharmaceutical
Authorities in the UK have reclassified Epidyolex (cannabidiol) as a Schedule 5 drug, the lowest level of control, making it easier for the company to distribute the therapy. 24 June 2020
Pharmaceutical
Akili, a funded entity of London-listed biotech firm PureTech Health, today announced that it has received a Conformité Européenne (CE) Mark for EndeavorRx (AKL-T01) as a prescription-only digital therapeutic software intended for the treatment of attention and inhibitory control deficits in pediatric patients with attention deficit hyperactivity disorder (ADHD). 23 June 2020
Biotechnology
Sarepta Therapeutics aims to expand its gene therapy capability via a global research and option agreement with Codiak BioSciences. 22 June 2020
Pharmaceutical
Last week’s regulatory news included Viela Bio gaining its first product approval, with the US Food and Drug Administration clearing its neuromyelitis optica spectrum disorder (NMOSD) candidate Uplizna (inebilizumab) for marketing, and Epizyme’s Tazverik won FDA approval for two follicular lymphoma indications. On the deal-making front, Neurocrine Biosciences entered a potential $2 billion collaboration with Japan’s Takeda to in-license seven pipeline programs for CNS indications, and investors welcomed Alpine Immune Sciences latest licensing accord, this one with AbbVie for its autoimmune disease candidate ALPN-101. 21 June 2020
Pharmaceutical
Hot on the heels of US regulatory clearance, Health Canada has also approved Kynmobi (apomorphine HCl) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD), says Sunovion. 18 June 2020
Biotechnology
Latest research findings show Emgality (galcanezumab-gnlm), which received regulatory approval in the USA and Europe in 2018, reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. 17 June 2020
Pharmaceutical
USA-based Neurocrine Biosciences and Japan’s largest drugmaker Takeda Pharmaceutical yesterday inked a collaboration deal that clearly please both sets of investors, as the companies saw their share prices rise. 17 June 2020
Biotechnology
London-listed biotech firm PureTech Health’s founded entity, Akili Interactive, has gained US Food and Drug Administration clearance for EndeavorRx (AKL-T01) as a prescription treatment for children with attention-deficit/hyperactivity disorder (ADHD). 16 June 2020
Pharmaceutical
Privately-held Seattle-based CNS specialist Impel NeuroPharma has announced positive results from the Phase III STOP 301 study of INP104 (DHE) in acute migraine. 11 June 2020
Pharmaceutical
June 9th is International Batten Disease Awareness Day. We take this opportunity to explore the current therapeutic landscape for Batten disease and discuss some of the emerging therapies offering hope for the future. 9 June 2020
Biotechnology
In a second major deal within three months for the Oxford University, UK, biotech spinout Evox Therapeutics, the company today announced a research collaboration and license agreement with Eli Lilly to leverage Evox’ proprietary DeliverEX platform. 9 June 2020
Generics
The US District Court for the District of New Jersey has ruled in favor of the Israel-based generics giant Teva in a patent infringement lawsuit regarding a generic version of Narcan (naloxone HCl) nasal spray for the treatment of opioid overdose. 8 June 2020
Pharmaceutical
Belgium’s largest drugmaker UCB today announced the acquisition of Engage Therapeutics, a New Jersey, USA-based clinical-stage pharmaceutical company developing Staccato alprazolam for the rapid termination of an active epileptic seizure. 5 June 2020
Biotechnology
Life sciences venture capital firm Forbion says that its newest portfolio company, Prilenia Therapeutics, a Naarden, Netherlands- and Herzliya, Israel-based clinical stage biotech company, has raised $62.5 million in a Series A financing round. 4 June 2020
Pharmaceutical
For the first time in more than five years, a new prescription treatment option is available in the USA for adult patients with insomnia. 1 June 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze